(Bloomberg) – A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended the production and sales of the drug, which doubts the future of treatment. The drug’s license has expired and its renewal is now in the final stages of a regulatory review, during which Green Valley Pharmaceutical Co. In ‘NE post statement to Bloomberg News, stop. The Shanghai-based drugmaker informed employees of the production in an internal notice at the end of May, local media Yicai first reported on Monday. Green Valley’s drug-a compound located by the seaweed, known as sodium oligyphanate, or GV-971-is-considered a major progress when China’s drug regulator gave it conditional approval in 2019, as the first new therapy was approved in 17 years for Alzheimers. Local and international medical experts have since questioned how effective it is to delay or reverse the cognitive declines of Alzheimer’s patients, given the relatively short duration of and the inconsistent results shown-the clinical trial in China. The company launched a global clinical trial in 2020 to enroll about 2000 patients across China, the US and Europe. It ended two years later due to a lack of funding and covid pandemic disruption. Green Valley had previously conducted clinical studies to marketing about 3.300 patients on sodium oil novel in China and, according to the company, planned to present the results at an international academic conference. The changes are temporary and limited to activities associated with sodium omby, the company said, adding that medicine offer for clinical trials is not affected. “We are in close communication with relevant authorities and believe that patients’ treatment needs will be met soon,” the email says. The company that is kept carefully did not disclose the sales revenue for GV-971 in China, where it was included in 2022 for the compensation of national insurance at a price of about $ 41 per subject. GV-971 hospital and retail sales that year had $ 45.4 million (326 million yuan) on top, reports Yicai, citing Pharnexcloud-database of National Hospital Sales in China. China has since approved two new Alzheimer’s therapies developed by multinational drugs: Biogen Inc. and Eisai Co. Leqembi, and Kisunla of Eli Lilly & Co. The country has 17 million dementia patients – about 30% of the global total – per 2024 report led by Shanghai Jiao Tong University School of Medicine. More stories like these are available on Bloomberg.com © 2025 Bloomberg LP
Chinese firm stops the production of controversial Alzheimer -Aid | Company Business News
